Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Decreases By 22.9%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totalling 431,400 shares, a drop of 22.9% from the March 31st total of 559,500 shares. Based on an average trading volume of 312,600 shares, the short-interest ratio is presently 1.4 days.

Milestone Pharmaceuticals Stock Performance

MIST traded down $0.04 during midday trading on Friday, reaching $1.54. The company’s stock had a trading volume of 469,849 shares, compared to its average volume of 138,660. The stock has a market cap of $81.85 million, a P/E ratio of -1.11 and a beta of 1.77. The company has a fifty day simple moving average of $1.67 and a 200 day simple moving average of $2.06. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 2.97. Milestone Pharmaceuticals has a twelve month low of $1.33 and a twelve month high of $4.49.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Thursday, March 21st. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Research analysts expect that Milestone Pharmaceuticals will post -1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MIST. Piper Sandler cut their target price on shares of Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, March 22nd.

Institutional Trading of Milestone Pharmaceuticals

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. BML Capital Management LLC grew its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 62.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 442,352 shares of the company’s stock after acquiring an additional 169,852 shares during the quarter. Milestone Pharmaceuticals accounts for about 0.6% of BML Capital Management LLC’s holdings, making the stock its 23rd largest position. BML Capital Management LLC owned 1.32% of Milestone Pharmaceuticals worth $739,000 at the end of the most recent reporting period. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.